Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.32 USD | -4.93% | +2.77% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Business Summary
Number of employees: 31
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel, Oral Small Molecule Therapies for Neuroscience, Inflammation and Immunology Indications
100.0
%
| 0 | nan % | 50 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 50 | 100.0 % | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,729,172 | 0 | 0 | 65.58 % |
Stock B | 1 | 18,994,104 | 16,869,868 ( 88.82 %) | 0 |
Company contact information
Pipeline Therapeutics, Inc.
10578 Science Center Drive Suite 200
92121, San Diego
+
http://www.contineum-tx.comSector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 405M | |
+68.25% | 62.86B | |
-1.09% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.35% | 26.46B | |
-22.06% | 18.9B | |
+4.24% | 12.67B | |
+24.15% | 12.27B | |
+28.22% | 12.07B |
- Stock Market
- Equities
- CTNM Stock
- Company Contineum Therapeutics, Inc.